Data gathered: April 15
AI Stock Analysis - Summit Therapeutics (SMMT)
Analysis generated October 30, 2024. Powered by Chat GPT.
Summit Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company primarily targets infectious diseases and other unmet medical needs. With a dedicated research team and a strong pipeline, Summit Therapeutics has established itself as a notable player in the pharmaceutical sector.
Stock Alerts - Summit Therapeutics (SMMT)
 |
Summit Therapeutics | April 14 Price is up by 7% in the last 24h. |
|
Summit Therapeutics | April 11 Price is up by 12.2% in the last 24h. |
|
Summit Therapeutics | April 10 Price is up by 8.1% in the last 24h. |
|
Summit Therapeutics | April 9 Price is up by 7.6% in the last 24h. |
Alternative Data for Summit Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 78 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 262 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,947 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,969 | Sign up | Sign up | Sign up |
| Twitter Mentions | 144 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 211 | Sign up | Sign up | Sign up |
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI).
| Price | $25.05 |
| Target Price | Sign up |
| Volume | 8,170,000 |
| Market Cap | $17.1B |
| Year Range | $9.4 - $31.93 |
| Dividend Yield | 0% |
| PE Ratio | 26.36 |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday?April 14 - Yahoo |
 |
U.S. Indexes Rose Monday; Summit Therapeutics Led IncreasesApril 14 - Biztoc.com |
|
Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial OfficerApril 14 - Yahoo |
|
Here's Why Summit Therapeutics Stock Soared 15% on FridayApril 13 - Yahoo |
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing CompetitionApril 13 - SeekingAlpha |
|
 |
National Bank of Canada FI Acquires New Shares in Summit Therapeutics Inc. (NASDAQ:SMMT)April 13 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 0 | 0 | 0 | -61M | -61M | -0.063 |
| Q3 '24 | 0 | 20,000 | -20,000 | -56M | -54M | -0.080 |
| Q2 '24 | 0 | 20,000 | -20,000 | -60M | -57M | -0.090 |
| Q1 '24 | 0 | 27,000 | -27,000 | -43M | -41M | -0.060 |
| Q4 '23 | -240,000 | 610,000 | -840,000 | -37M | -33M | -0.052 |
Insider Transactions View All
| Zanganeh Mahkam filed to buy 50,000 shares at $3.7. March 27 '24 |
| Zanganeh Mahkam filed to buy 520,814 shares at $3.7. March 27 '24 |
| Zanganeh Mahkam filed to buy 24,923,800 shares at $3.7. March 27 '24 |
| Zanganeh Mahkam filed to buy 30,000 shares at $3.8. March 27 '24 |
| Dhingra Ankur filed to buy 354,958 shares at $3.8. March 27 '24 |
Similar companies
Read more about Summit Therapeutics (SMMT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Summit Therapeutics?
The Market Cap of Summit Therapeutics is $17.1B.
What is Summit Therapeutics' PE Ratio?
As of today, Summit Therapeutics' PE (Price to Earnings) ratio is 26.36.
What is the current stock price of Summit Therapeutics?
Currently, the price of one share of Summit Therapeutics stock is $25.05.
How can I analyze the SMMT stock price chart for investment decisions?
The SMMT stock price chart above provides a comprehensive visual representation of Summit Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Summit Therapeutics shares. Our platform offers an up-to-date SMMT stock price chart, along with technical data analysis and alternative data insights.
Does SMMT offer dividends to its shareholders?
As of our latest update, Summit Therapeutics (SMMT) does not offer dividends to its shareholders. Investors interested in Summit Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Summit Therapeutics?
Some of the similar stocks of Summit Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.